Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gillian M Borthwick

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
BJC Reports|July 4, 2024
A novel colorectal cancer test combining microsatellite instability and <i>BRAF/RAS</i> analysis: Clinical validation and impact on Lynch syndrome screeningRichard Gallon, Patricia Herrero-Belmonte, Rachel Phelps, et al.
European Journal of Human Genetics : EJHG|February 15, 2024
Identification of people with Lynch syndrome from those presenting with colorectal cancer in England: baseline analysis of the diagnostic pathwayFiona E McRonald, Joanna Pethick, Francesco Santaniello, et al.
The Journal of Clinical Investigation|November 5, 2003
Mitochondrial DNA mutations in human colonic crypt stem cellsRobert W Taylor, Martin J Barron, Gillian M Borthwick, et al.
Human Mutation|September 1, 2019
Sequencing-based microsatellite instability testing using as few as six markers for high-throughput clinical diagnosticsRichard Gallon, Harsh Sheth, Christine Hayes, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 25, 2022
Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-upJohn C Mathers, Faye Elliott, Finlay Macrae, et al.
Lancet (London, England)|June 15, 2020
Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trialJohn Burn, Harsh Sheth, Faye Elliott, et al.
International Journal of Cancer|October 10, 2022
Is HLA type a possible cancer risk modifier in Lynch syndrome?Aysel Ahadova, Johannes Witt, Saskia Haupt, et al.
Human Mutation|February 12, 2019
A sensitive and scalable microsatellite instability assay to diagnose constitutional mismatch repair deficiency by sequencing of peripheral blood leukocytesRichard Gallon, Barbara Mühlegger, Sören-Sebastian Wenzel, et al.
The Lancet. Gastroenterology & Hepatology|July 9, 2026
Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trialJohn Burn, Gillian M Borthwick, Faye Elliott, et al.
Gastroenterology|December 31, 2022
Constitutional Microsatellite Instability, Genotype, and Phenotype Correlations in Constitutional Mismatch Repair DeficiencyRichard Gallon, Rachel Phelps, Christine Hayes, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
BJC Reports|July 4, 2024
A novel colorectal cancer test combining microsatellite instability and <i>BRAF/RAS</i> analysis: Clinical validation and impact on Lynch syndrome screeningRichard Gallon, Patricia Herrero-Belmonte, Rachel Phelps, et al.
European Journal of Human Genetics : EJHG|February 15, 2024
Identification of people with Lynch syndrome from those presenting with colorectal cancer in England: baseline analysis of the diagnostic pathwayFiona E McRonald, Joanna Pethick, Francesco Santaniello, et al.
The Journal of Clinical Investigation|November 5, 2003
Mitochondrial DNA mutations in human colonic crypt stem cellsRobert W Taylor, Martin J Barron, Gillian M Borthwick, et al.
Human Mutation|September 1, 2019
Sequencing-based microsatellite instability testing using as few as six markers for high-throughput clinical diagnosticsRichard Gallon, Harsh Sheth, Christine Hayes, et al.
Cancer Prevention Research (Philadelphia, Pa.)|July 25, 2022
Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-upJohn C Mathers, Faye Elliott, Finlay Macrae, et al.
Lancet (London, England)|June 15, 2020
Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trialJohn Burn, Harsh Sheth, Faye Elliott, et al.
International Journal of Cancer|October 10, 2022
Is HLA type a possible cancer risk modifier in Lynch syndrome?Aysel Ahadova, Johannes Witt, Saskia Haupt, et al.
Human Mutation|February 12, 2019
A sensitive and scalable microsatellite instability assay to diagnose constitutional mismatch repair deficiency by sequencing of peripheral blood leukocytesRichard Gallon, Barbara Mühlegger, Sören-Sebastian Wenzel, et al.
The Lancet. Gastroenterology & Hepatology|July 9, 2026
Aspirin for cancer prevention in individuals with Lynch syndrome: first results from the CaPP3 multicentre, randomised, double-blind, non-inferiority trialJohn Burn, Gillian M Borthwick, Faye Elliott, et al.
Gastroenterology|December 31, 2022
Constitutional Microsatellite Instability, Genotype, and Phenotype Correlations in Constitutional Mismatch Repair DeficiencyRichard Gallon, Rachel Phelps, Christine Hayes, et al.
Pageof 2